Hematopoietic SCT (HSCT) has become an established therapy for numerous disorders of the hematopoietic system and for some solid tumors. 1 However, owing to the high cost of the procedure, and the need for a multidisciplinary team, few centers in developing countries provide this treatment modality. In Mexico, the history of HSCT began in 1980, when the first transplant took place at the National Institute of Nutrition in Mexico City. After this, there were a few other procedures in the National Medical Center of the University Hospital of Monterrey, with poor results. This resulted in the suspension of the HSCT program at these institutions. As a result, the practice of HSCT in Me´xico was almost anecdotal until 1995. 2 As there has been no national report, we consider it important to evaluate the current activity, needs and perspectives in the field of HSCT.
As there is no national database, only general information was requested from patients o18 years of age at the seven pediatric transplant centers for 2007 and 2008. The data requested were number of transplants per center, type of transplant, indication for allogeneic HSCT (allo-HSCT), indication for autologous HSCT (auto-HSCT), type of conditioning regimen, source of stem cells (BM, peripheral blood and cord blood), type of donor for allo-HSCT (matched sibling donor, unrelated donor and mismatched family donor). The total number of transplants was 127 (55 in 2007 and 72 in 2008) with a transplant rate of 1.57 and 2.05 per million population, respectively. Regarding the type of transplant, 22% of the children underwent auto-HSCT, whereas 78% underwent allo-HSCT. In the allo-HSCT group, 64.6% underwent transplantation for malignant diseases. The most common indication for auto-HSCT was AML. A myeloablative conditioning regimen was used in 54% of the allografts. Peripheral blood was the most common source of HSC. Among the recipients of allo-HSCT, the donor was a matched sibling donor in 62.6% of the cases (Table 1) .
This report includes the initial results of an effort to gather this information from several transplant centers in Mexico, in order to provide a starting point to establish a central authority that is able to gather, analyze and disseminate the transplant activity in the country. There are significant economic, political and socio-cultural limitations to performing HSCT, as Me´xico is one of the leading countries regarding economic inequality (http:// www.who.int/countries/mex/en/). Owing to lack of adequate statistics of the incidence of diseases requiring HSCT, it is almost impossible to establish a calculation based on the needs of our population. To the best of our knowledge, there is no report on the overall pediatric transplant activity in Latin-American countries.
The pediatric population in Mexico is approximately 35 million (http://www.census.gov.), so the team density is 2 (transplant teams per 10 million pediatric population) and the team distribution 0.035 (transplant teams per 10 000 km 2 ). Our activity is well below that in Spain, a developed country with certain genetic similarities in common with us, who in 2008, with a pediatric population of approximately 6.51 million, performed 205 HSCTs in children.
3 However, our activity is similar to that reported by countries with similar socioeconomic conditions, such as some eastern European nations. 4 Probably our data are lower than the actual activity, but serve as an overview to raise awareness of the fact that the current activity is far below national requirements; the main factor is economic, but is also influenced by the lack of information, and shortcomings in the organization of our health system. The number of auto-HSCTs was low and the indication for solid tumors was extremely low. 4, 5 According to the literature in the autologous setting, the use of PBSCs has almost completely replaced BM. 6 Lympho-myeloproliferative disorders were the most common indication for allo-HSCT, but the use of reduced-intensity conditioning (mainly consisting of fludarabine/BU or fludarabine/melphalan) was high compared with other countries; this is mainly related to economic restrictions and the experience of this procedure at two of the centers. 7, 8 Another important difference is the high percentage of peripheral blood in allo-HSCT, the Spanish group showing low rates of G-CSF-related acute side effects in children. There is no evidence to suggest an increased risk of malignancy associated with a short course of G-CSF, 9 but it would be interesting to perform a study to analyze the incidence of GVHD. The percentage of mismatched family donors was very low, which is explained by the economic problems related to post transplant complications and the use of lymphocyte depletion. 4, 5 The cost of transplantation is a debatable issue in our country, varying from 15 000 to 100 000 USD. Recently, the federal health authority has begun sponsoring the cost of HSCT for the population lacking health services. In Mexico, approximately 42% of the population has social security services, about 5% have private health insurance and 53% have no health cover. However, logistic problems remain: delay in patient referral, having limited access to a transplant center, having few teams per inhabitant, having to travel long distances to a transplant center, and incurring extra expenses for the patient, such as transportation, accommodations and food, all of this in a country where the minimum salary is approximately 4.1-4.4 USD per day.
In addition to gathering transplant information at a very detailed level by a central organization, the two major challenges for the future are to define the rules for optimal allocation of resources based on health needs and qualification of available medical care, and to set up a system that is able to provide an objective assessment of the performance of centers. To establish the status of HSCT and to meet the future needs, a qualified registry system is essential. A unified patient and donor registration database may be a worthwhile project that must be backed by the Mexican Society of Hematology. Observational databases may facilitate an understanding of transplant outcomes by addressing questions that are difficult to answer in randomized trials and also aid in the development of optimal strategies for prospective clinical trials. 10 Knowledge of current activity will allow for defining a more effective healthcare planning and for a better definition of transplant indications, and should significantly improve the quality of medical research and clinical outcome.
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